Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO)
ConclusionThe addition ofweekly carboplatin to neoadjuvant paclitaxel and dd EC leads to a pCR rate comparable to prior studies (54%). However, hematological toxicity and febrile neutropenia rate was unexpectedly high. Future investigations could focus on reversing the sequence, which may lead to better hematological tolerability.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Belgium Health | Brain | Breast Cancer | Cancer | Cancer & Oncology | Hematology | Neoadjuvant Therapy | Neurology | Neurosurgery | Peripheral Neuropathy | Study | Thrombocytopenia | Toxicology